Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study

Abuaf, Amanda Frisosky; Javed, Adil; Bunting, Samuel R.; Carroll, Timothy J.; Reder, Anthony T.; Cipriani, Veronica

doi:10.1016/j.msard.2023.104523

Cited by 4 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective study was conducted on Black and White pwMS on ocrelizumab with MRIs being obtained in a proportion of the study subjects at baseline and year two ( 12 ). No significant differences were present between groups comparing cortical grey matter thickness, along with volumes of the thalamus, caudate, putamen, and brainstem ( 12 ).…”

Section: Adult Ms Studiesmentioning

confidence: 99%

“…Such additional investigation may guide more personalized treatment strategies, which is important given those of African American descent have been shown to respond less well to interferons ( 9 ), but reasonably well to natalizumab ( 10 ), dimethyl fumarate ( 11 ), and ocrelizumab ( 12 ), both clinically and from a neuroimaging perspective. It has also been shown that African American pwMS repopulate their B-cells more quickly than White pwMS, with 33% of African Americans with MS or neuromyelitis optica (NMO) repleting their B-cells, compared to 0% of White patients with MS or NMO between 6 to 12 months after anti-CD20 therapy ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

“…persons No significant differences between groups with respect to cortical grey matter thickness; volumes of caudate, putamen, thalamus, brainstem(12) DMT, disease-modifying therapy; MS, multiple sclerosis; pwMS, people with MS.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Do magnetic resonance imaging features differ between persons with multiple sclerosis of various races and ethnicities?

et al. 2023

View full text Add to dashboard Cite

Those of African American or Latin American descent have been demonstrated to have more severe clinical presentations of multiple sclerosis (MS) than non-Latin American White people with MS. Concurrently, radiological burden of disease on magnetic resonance imaging (MRI) in African Americans with MS has also been described as being more aggressive. Here, we review MRI studies in diverse racial and ethnic groups (adult and pediatric) investigating lesion burden, inflammation, neurodegeneration, and imaging response to disease modifying therapy. We also discuss why such disparities may exist beyond biology, and how future studies may provide greater insights into underlying differences.

show abstract

Section: Adult Ms Studiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Do magnetic resonance imaging features differ between persons with multiple sclerosis of various races and ethnicities?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Studies leveraging real-world data have started to fill these gaps, providing insights into the drug’s performance outside the controlled environment of clinical trials [ 9 , 10 ]. Real-world studies have generally supported the controlled trial data, suggesting that ocrelizumab can reduce relapse rates and magnetic resonance imaging (MRI) shows evidence of disease activity in a broader, less-selected patient population [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis

Schuldesz,

Maganti,

Tudor

et al. 2024

Diseases

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic, progressive neurological disorder that significantly impacts quality of life and functionality. Ocrelizumab, a monoclonal antibody targeting CD20-positive B cells, has emerged as a treatment for relapsing-remitting MS (RRMS). This study aimed to assess the impact of ocrelizumab on disease progression and quality of life over a longitudinal course, utilizing clinical criteria and magnetic resonance imaging (MRI) analyses. Conducted at the Neurology Department of Pius Brinzeu Clinical Emergency Hospital in Western Romania from 2020 to 2023, this observational study enrolled 93 patients with RRMS who commenced ocrelizumab therapy. The study employed the Expanded Disability Status Scale (EDSS) and MRI to evaluate disease progression, while quality of life was assessed using the World Health Organisation Quality of Life (WHOQOL) questionnaire, Beck Depression Index (BDI), and MOCA scales. Significant improvements were observed post-treatment. EDSS scores decreased from 4.61 to 4.08 (p = 0.038), indicating reduced disability. MRI analyses showed a substantial decrease in expansive lesions (from 67.74% to 26.88%, p < 0.001) and an increase in stationary lesions (from 32.26% to 73.12%, p < 0.001). Quality of life improvements were notable in the physical (from 58.42 to 64.84, p = 0.005) and environmental domains (from 63.21 to 68.44, p = 0.033). Cognitive functions, assessed via Montreal Cognitive Assessment (MOCA), showed a significant total score increase from 20.38 to 22.30 (p < 0.001). Subgroup analysis revealed more pronounced effects in females and younger patients, with a significant reduction in depressive symptoms measured by BDI scores (from 14.35 to 11.62, p = 0.003). Ocrelizumab significantly reduced disease activity and disability in RRMS patients, as demonstrated by improvements in EDSS scores and MRI findings. Quality of life and cognitive functions also showed considerable enhancements. These findings support ocrelizumab’s efficacy in not only managing MS symptoms but also improving overall patient well-being.

show abstract

Real world study of ocrelizumab in multiple sclerosis: Kuwait experience

Alroughani,

AlMojel,

Al-Hashel

et al. 2023

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study

Cited by 4 publications

References 31 publications

Do magnetic resonance imaging features differ between persons with multiple sclerosis of various races and ethnicities?

Do magnetic resonance imaging features differ between persons with multiple sclerosis of various races and ethnicities?

Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis

Real world study of ocrelizumab in multiple sclerosis: Kuwait experience

Contact Info

Product

Resources

About